Cargando…

Prognostic value of PD‐L1 expression in combination with CD8(+) TILs density in patients with surgically resected non‐small cell lung cancer

To investigate the prognostic value of PD‐L1 expression combined with CD8(+) TILs density in patients with resected NSCLC and correlations with clinicopathological features. We retrospectively enrolled 178 patients with resected NSCLC from 2011 to 2015. All surgical primary and 58 matched metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hui, Shi, Jinpeng, Lin, Dongmei, Li, Xuefei, Zhao, Chao, Wang, Qi, Zhang, Limin, Jiang, Tao, Zhao, Sha, Liu, Xiaozhen, Jia, Yijun, Zhang, Yajun, Cai, Weijing, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773962/ https://www.ncbi.nlm.nih.gov/pubmed/29168339 http://dx.doi.org/10.1002/cam4.1243

Ejemplares similares

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer
por: Zhang, Limin, et al.
Publicado: (2019)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
por: Ni, Yunbi, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis
por: Zhao, Sha, et al.
Publicado: (2016)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Prognostic significance of PD-L1 expression and CD8(+) TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: a retrospective study
por: Cheng, Xiaomin, et al.
Publicado: (2022)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
por: Han, Ruoshuang, et al.
Publicado: (2021)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

High post‐chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy
por: Jia, Wenxiao, et al.
Publicado: (2023)

Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer
por: Jia, Yijun, et al.
Publicado: (2017)

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
por: Zurlo, Ina Valeria, et al.
Publicado: (2021)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

Lipids for CD8(+) TILs: Beneficial or harmful?
por: Wu, Duojiao, et al.
Publicado: (2022)

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Gennen, Kathrin, et al.
Publicado: (2020)

Uncovering PD-L1 and CD8(+) TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma
por: Chen, Jingjing, et al.
Publicado: (2020)

Concordance of PD-L1 expression and CD8(+) TIL intensity between NSCLC and synchronous brain metastases
por: Batur, Sebnem, et al.
Publicado: (2020)

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells
por: Caraban, Bogdan Marian, et al.
Publicado: (2023)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
por: Wang, Jian‐Hua, et al.
Publicado: (2019)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

PD-L1 in Combination with CD8(+)TIL and HIF-1α are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma
por: Zhou, Zihan, et al.
Publicado: (2020)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
por: Pan, Hui, et al.
Publicado: (2016)

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Prognostic value of aberrantly expressed methylation genes in human hepatocellular carcinoma
por: Zhen, Limin, et al.
Publicado: (2020)

Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer
por: Ju, Xiaoli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cg8jbqaqujgqe7c5ko3k7f9ca3